A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International

摘要: Summary Objectives:  To compare alendronate 70 mg once weekly (OW) with risedronate 35 mg OW respect to change in bone mineral density (BMD), biochemical markers and upper gastrointestinal (UGI) tolerability over 24 months. Methods:  This was a 12-month extension the Fosamax® Actonel® Comparison Trial international study (FACTS). Postmenopausal women osteoporosis randomly assigned either or for base continued taking same double-blind medication. Efficacy measurements were BMD at hip trochanter, lumbar spine, total hip, femoral neck levels of four turnover 24 months. The primary hypothesis that would produce greater mean per cent increase from baseline trochanter 24 months. Results:  Trochanter increased significantly month 24 both groups, larger alendronate: adjusted treatment difference 1.50% (95% confidence interval: 0.74%, 2.26%; p < 0.001). Similar results seen all sites. Significant geometric decreases (p < 0.001) differences ranged 8.9% 25.3%. No significant incidence UGI other adverse events. Conclusions:  Alendronate yielded gains marker than 24 months, no tolerability.